Nov 5 (Reuters) - Contract drug manufacturer Catalent (CTLT.N), opens new tab, which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below ...

At the same time, Catalent is one of the “very few” contract drug manufacturers that provides specialized development and manufacturing services to companies that sell these medicines.

BALTIMORE -- Maryland election officials are anticipating a record turnout at the polls this year. Voters can cast their ballots in person starting Thursday morning at more than 90 Maryland early ...

Investors eyeing a purchase of Catalent Inc (Symbol: CTLT) stock, but tentative about paying the going market price of $59.14/share, might benefit from considering selling puts among the ...

Some rates use different ages or coverage limits. Erie and State Farm offer the best mix of low rates and great customer service in Maryland. Both companies offer online quotes, so you can quickly ...

BALTIMORE - Abortion rights are front and center on the 2024 Maryland election ballot with Question 1. Abortion is legal in Maryland. However, state lawmakers last year passed an amendment that ...

Update 12:30pm: Adds Catalent response. The CEO of Swiss pharmaceuticals behemoth Roche (OTCQX:RHHBY) said he believes antitrust regulators should not allow Novo Holdings to purchase Catalent ...

Stefano Fendrich and Thomas Johnson reporting from College Park, Maryland. The Trojans travel across the country to take on Maryland after losing three of their last four. We’re reporting live from ...

If you’re considering enrolling in a Medicare Advantage plan (also known as Medicare Part C) in Maryland to meet your various health insurance needs, you’re far from alone. There are multiple ...

Catalent CTLT recently announced that it has entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in Somerset, NJ, to Ardena. Ardena is a ...

Catalent, Inc. CTLT reported first-quarter fiscal 2025 adjusted loss per share of 13 cents, flat year over year. The figure was wider than the Zacks Consensus Estimate of a loss of 11 cents per ...

Jefferies analyst David Windley maintained a Hold rating on Catalent (CTLT – Research Report) today and set a price target of $63.50. David Windley has given his Hold rating due to a combination ...